- Home
- MTR vs PHGE Comparison
MTR vs PHGE Comparison
Compare MTR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- PHGE
- Stock Information
- Founded
- MTR 1979
- PHGE 2015
- Country
- MTR United States
- PHGE Israel
- Employees
- MTR N/A
- PHGE N/A
- Industry
- MTR Oil & Gas Production
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- MTR Energy
- PHGE Health Care
- Exchange
- MTR Nasdaq
- PHGE Nasdaq
- Market Cap
- MTR 11.8M
- PHGE 11.1M
- IPO Year
- MTR N/A
- PHGE N/A
- Fundamental
- Price
- MTR $6.33
- PHGE $0.61
- Analyst Decision
- MTR
- PHGE Strong Buy
- Analyst Count
- MTR 0
- PHGE 2
- Target Price
- MTR N/A
- PHGE $22.50
- AVG Volume (30 Days)
- MTR 14.1K
- PHGE 73.2K
- Earning Date
- MTR 01-01-0001
- PHGE 11-14-2024
- Dividend Yield
- MTR 3.56%
- PHGE N/A
- EPS Growth
- MTR N/A
- PHGE N/A
- EPS
- MTR 0.35
- PHGE N/A
- Revenue
- MTR $966,169.00
- PHGE N/A
- Revenue This Year
- MTR N/A
- PHGE N/A
- Revenue Next Year
- MTR N/A
- PHGE N/A
- P/E Ratio
- MTR $18.20
- PHGE N/A
- Revenue Growth
- MTR N/A
- PHGE N/A
- 52 Week Low
- MTR $5.60
- PHGE $0.48
- 52 Week High
- MTR $14.49
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- MTR 43.26
- PHGE 42.68
- Support Level
- MTR $6.06
- PHGE $0.61
- Resistance Level
- MTR $6.79
- PHGE $0.69
- Average True Range (ATR)
- MTR 0.31
- PHGE 0.08
- MACD
- MTR -0.10
- PHGE 0.01
- Stochastic Oscillator
- MTR 20.77
- PHGE 10.05
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.